Literature DB >> 2033722

Characterization of fibronectin attachment by a human transitional cell carcinoma line, T24.

D E Coplen1, E J Brown, J McGarr, T L Ratliff.   

Abstract

The ability of transitional cell carcinoma cells to adhere to and invade the extracellular matrix is important in invasion and metastasis. The glycoprotein fibronectin is associated with laminin and Type IV collagen in the bladder basement membrane. We characterized the interaction between T-24 cells, a cell line derived from an invasive transitional cell tumor, and fibronectin. The cells use the alpha 5 beta 1 heterodimeric integrin receptor complex to mediate adherence via the classical (RGDS) fibronectin binding site. The importance of the alpha 5 beta 1 receptor to T-24 function is unknown and under investigation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2033722     DOI: 10.1016/s0022-5347(17)38621-4

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  5 in total

Review 1.  The mechanism of action of BCG therapy for bladder cancer--a current perspective.

Authors:  Gil Redelman-Sidi; Michael S Glickman; Bernard H Bochner
Journal:  Nat Rev Urol       Date:  2014-02-04       Impact factor: 14.432

2.  Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediated antitumour activity.

Authors:  R Nadler; Y Luo; W Zhao; J K Ritchey; J C Austin; M B Cohen; M A O'Donnell; T L Ratliff
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

3.  Characterization of the internalization of bacillus Calmette-Guerin by human bladder tumor cells.

Authors:  K Kuroda; E J Brown; W B Telle; D G Russell; T L Ratliff
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

4.  FimH confers mannose-targeting ability to Bacillus Calmette-Guerin for improved immunotherapy in bladder cancer.

Authors:  Yang Zhang; Fan Huo; Qiang Cao; Ru Jia; Qiju Huang; Zhu A Wang; Dan Theodorescu; Qiang Lv; Pengchao Li; Chao Yan
Journal:  J Immunother Cancer       Date:  2022-03       Impact factor: 12.469

Review 5.  BCG in Bladder Cancer Immunotherapy.

Authors:  Song Jiang; Gil Redelman-Sidi
Journal:  Cancers (Basel)       Date:  2022-06-23       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.